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BACKGROUND: It can be hypothesised that inherited polymorphisms in the drug-transporter ABCB1 gene may interfere with
interindividual variations in drug response in breast cancer patients. Docetaxel is a substrate for ABCB1 whose function has been
shown to be modulated by oestrogen and progesterone.
METHODS: Whether ABCB1 polymorphisms including T-129C, A61G, C1236T, G2677T/A and C3435T polymorphisms could account
for variations in the disposition of docetaxel and whether menopausal status at the time of diagnosis might interact with this effect
were analysed in women receiving neoadjuvant chemotherapy for breast cancer (n¼86).
RESULTS: A highly significant association was observed, but restricted to premenopausal women (n¼53), between the
pharmacokinetics of docetaxel and C3435T polymorphism, as patients with CC genotype had lower mean values of the area
under the plasma concentration-time curve (AUC) of docetaxel than patients with CT and TT genotypes (Po0.0001). Comparison
between pre- and postmenopausal women with the same C3435T genotype yielded a significant difference in docetaxel AUC only
for CC genotype (Po0.0001).
CONCLUSION: These results suggest that C3435T polymorphism genotyping and menopausal status at the time of diagnosis might be
useful when considering chemotherapy regimens including docetaxel in breast cancer patients.
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Taxanes, drugs frequently used to treat breast cancer, are
substrates for the ATP-binding cassette (ABC) transporter ABCB1
(Scala et al, 1997). This protein was initially discovered as an efflux
transporter involved in multidrug resistance of tumour cells
(Gottesman et al, 2002). However, ABCB1 is also physiologically
expressed at the apical surface of epithelial cells in various organs
responsible for drug disposition such as the intestine, liver and
kidney and at the apical surface of endothelial cells controlling the
availability of drugs at the blood–tissue interface (Schinkel, 1997).
ABCB1 is therefore also involved in drug metabolism by having a
role in the so-called phase 0 (efflux of unmodified drug) of the
metabolism of xenobiotics.
Breast cancer patients treated with taxanes such as docetaxel
show major interindividual variations in drug response, which
might be at least partly because of inherited polymorphisms in
genes encoding proteins involved in drug efflux including ABCB1
transporter (Relling and Dervieux, 2001; Rodrigues et al, 2008).
Since the first systematic screening for polymorphisms in ABCB1
coding region and the report of a functional polymorphism
(Hoffmeyer et al, 2000), 445 polymorphisms have been described
in coding regions, the promoter and non-coding regions (Kroetz
et al, 2003). The polymorphisms for which the frequency of
the variant allele is 45% include the T-129C in the promoter
region, the synonymous C1236T (exon 12) and C3435T (exon 26)
polymorphisms and the non-synonymous A61G (exon 2) and
G2677T/A (exon 21) polymorphisms.
There is evidence that the sex steroids oestrogen and progest-
erone interfere with ABCB1 function as either substrates and/or
regulators of ABCB1 expression. Oestrogens such as oestrone and
oestriol have been shown to be a substrate of ABCB1 and to increase
ABCB1 protein levels (Kim and Benet, 2004; Evseenko et al,2 0 0 7 ) .
Moreover, although not a substrate of ABCB1, progesterone has
been reported to inhibit ABCB1-mediated efflux (Yang et al, 1989;
Barnes et al, 1996; Hamilton et al, 2001) and increase ABCB1 mRNA
(Piekarz et al, 1993) and ATPase activity (Barnes et al, 1996; Kim
and Benet, 2004).
To evaluate whether variations in disposition of docetaxel
because of ABCB1 polymorphisms could be involved in the res-
ponse variability of breast cancer patients, the pharmacokinetics of
this drug and inherited polymorphisms of ABCB1 gene including
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were analysed. Given that the hallmark of menopause is a decrease
in ovarian secretion of oestrogen and progesterone, we analysed
the effects of menopausal status at the time of diagnosis on
the relationships between ABCB1 polymorphisms and the phar-
macokinetics of docetaxel given in neoadjuvant chemotherapy
regimens.
PATIENTS AND METHODS
Patients
Women with breast cancer receiving neoadjuvant chemotherapy
were included in this study (n¼86), namely patients with tumours
larger than 20mm (T2, T3 and T4 tumours) and absence
of metastatic disease. Patient characteristics are listed in Table 1.
A majority of the patients were Caucasians (n¼66). Menopausal
status at the time of diagnosis was specified. Menopause was
defined as amenorrhea for at least 12 months. Mean age at
diagnosis was 41 years (range: 26–56) for premenopausal patients
and 61 years (range: 50–76) for postmenopausal patients.
Chemotherapy consisted of four cycles of doxorubicin
(60mgm
–2) and cyclophosphamide (600mgm
–2) followed by
four cycles of docetaxel (100mgm
–2). Trastuzumab was adminis-
tered to four patients during courses of docetaxel because of the
presence of cerbB2 amplification in tumour cells.
The protocol was approved by the independent ethics committee
of Pitie ´-Salpe ˆtrie `re Hospital, Paris, France and all patients
provided written informed consent before inclusion in the study
including specific written informed consent for the pharma-
cogenetic analysis.
Pharmacokinetics of docetaxel
Pharmacokinetic analysis was performed for the first course
of docetaxel. A limited sampling strategy was used according to
previously reported studies (Baille et al, 1997). Five heparinised
blood samples (5ml each) were required: immediately before
infusion, 5min before the end of infusion and 20min, 2h and 5h
after the end of infusion. After immediate centrifugation of the
blood samples, plasma was stored at  201C until further analysis.
Plasma concentrations of docetaxel were determined using
validated high-performance liquid chromatography methods with
UV detection (Vergniol et al, 1992). The analytical range for
docetaxel determination was 25–5000ngml
–1. Individual drug
clearances were estimated from docetaxel population pharmaco-
kinetic parameters (Bruno et al, 1998) using the POST HOC option
of NONMEM (Beal and Sheiner, 1998). The area under the plasma
concentration-time curve (AUC) was calculated as AUC ¼ dose/
clearance.
Genotype
Genomic DNA was extracted from whole blood (10ml) using
QIAamp DNA blood Maxi Kit (Qiagen, Hilden, Germany). T-129C
(rs3213619), A61G (rs9282564), C1236T (rs1128503) and C3435T
(rs1045642) polymorphisms were each analysed using two match-
ing primers and two TaqMan MGB probes labeled with 6-FAM or
VIC dye for allelic discrimination (assay IDs: C__27487486_10 and
C__7586657_20 for T-129C and C3435T, respectively and custom-
designed assays for A61G and C1236T with probes FAM
(50-AACTGAACGATAAAAG-30) and VIC (50-TTTAAACTGAACA
ATAAAAG-30) and FAM (50-TCAGGTTCAGGCCCTT-30) and VIC
(50-TCAGGTTCAGACCCTT-30), respectively, Applied Biosystems,
Courtaboeuf, France). DNA (2.5ml) was amplified with TaqMan
PCR Universal Master Mix (Applied Biosystems) and Assay Mix
(Applied Biosystems) in a final volume of 25ml. Forty cycles with
denaturation at 921C, and annealing and extension at 601C were
performed.
For G2677T/A (rs2032582) polymorphism, the analysis was
based on PCR-RFLP. The primer sequences designed by Primer3
software were 50-TGACAAACGTTAGGCTTAAATTACA-30 and
50-AAGATTGCTTTGAGGAATGGTT-30 for 2677F and 2677R,
respectively. DNA (2.5ml) was amplified with 1.25 U Ampli Taq
Gold DNA polymerase (Applied Biosystems), 200nM 2677F and
2677R primers (Proligo, Paris, France), 200mM dNTP, 4mM MgCl2
and GeneAmp Gold Buffer (Applied Biosystems) in a final volume
of 25ml. Forty cycles with denaturation at 951C, annealing at 631C
and extension at 721C were performed. The 726bp PCR product
(12.5ml) was submitted to 2.5 U Bse YI (New England Biolabs
Ozyme, Saint-Quentin en Yvelines, France) for 2h at 371C or 2.5 U
Rsa I (New England Biolabs Ozyme) for 3h at 371C. Bse YI cuts at
the G nucleotide yielding two fragments (590 and 136kb). Rsa I
enzyme cuts at the nonspecific 509 nucleotide and at the A variant
yielding two fragments (508 and 218kb) if A variant is absent, four
fragments (508, 218, 136 and 82kb) if one A allele is present and
three fragments (508, 136 and 82kb) if two A alleles are present.
Digested PCR products were submitted to electrophoresis in Novex
8% TBE gels (Invitrogen, Eragny sur Oise, France).
Statistical analysis
Mean values of AUC and mean values of clearance of docetaxel
were compared between groups using the nonparametric Mann–
Whitney test for two groups or the nonparametric Kruskal–Wallis
test for three or more groups (StatView software, version 5.0;
SAS Institute, Cary, NC, USA). Owing to multiple comparisons,
statistical significance was defined as Po0.005.
RESULTS
Plasma concentrations of docetaxel were determined in the 86
patients. Genotyping results for the T-129C, A61G, C1236T,
G2677T/A and C3435T polymorphisms, the two most frequent
Table 1 Patient characteristics (n¼86)
Mean (range)
or n (%)
Missing
data n
Age at diagnosis (years) 49 (26–76) 0
Ethnic group 0
Caucasian 66 (77%)
North African and sub-Saharan African 19 (22%)
Asian 1 (1%)
Menopausal status
a 0
Premenopausal 53 (62%)
Postmenopausal 33 (38%)
Age at menopause (years) 49 (42–59) 10
Height (cm) 163 (149–177) 0
Weight (kg) 67 (46–137) 0
BMI (kgm
 2) 25 (18–53) 0
Age at menarche (years) 13 (10–18) 42
Age at full-term pregnancy (years) 26 (15–37) 19
Parity 2 (0–10) 6
Ever hormone replacement therapy use 13 (48%) 6
Current smoker 11 (17%) 22
Tumour stage (T) 0
T2 (size 420mm and p50mm) 53 (62%)
T3 (size 450mm) 25 (29%)
T4 (inflammatory) 8 (9%)
Histologic type of breast cancer 0
IDC 76 (88%)
ILC 10 (12%)
Abbreviations: BMI¼body mass index; IDC¼invasive ductal carcinoma; ILC¼
invasive lobular carcinoma.
aMenopausal status refers to the menopausal status at the
time of diagnosis. Menopause was defined as amenorrhea for at least 12 months.
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phisms and the haplotype containing the homozygous variant
genotypes, which have a frequency X10%, are shown in
Table 2.
For each polymorphism, the mean AUC of docetaxel was
initially compared between each genotype using the nonparametric
Mann–Whitney test for two groups or the nonparametric
Kruskal–Wallis test for three or more groups. When a significant
relationship was found for a polymorphism, pairwise comparisons
were then performed between one genotype and the other
genotypes for this polymorphism considered as a single group.
The same analysis was performed for comparisons of mean
clearances between genotypes for each polymorphism. Similar
results were obtained whether AUC or clearances were considered
as pharmacokinetic parameters for docetaxel. However, there was
not always a strict correlation between AUC and clearance for a
given genotype. This is probably because of the fact that AUC
depends on docetaxel dose, which depends on body surface. The
results below will be focused on AUC (for details on clearance, see
the corresponding Tables).
A striking association was observed between the pharmacoki-
netics of docetaxel and menopausal status at diagnosis. Mean
values (± standard errors, s.e.) for AUC of docetaxel were lower in
premenopausal women (4124±612mghl
–1, n¼53) than in post-
menopausal women (4598±298mghl
–1, n¼33, Mann–Whitney
test P¼0.0008) (Figure 1).
The influence of menopausal status on the relationship between
ABCB1 polymorphisms and the pharmacokinetics of docetaxel was
analysed. Results regarding the pharmacokinetics of docetaxel
according to ABCB1 polymorphisms in pre- and postmenopausal
patients are summarised in Tables 3 and 4, respectively.
A significant association between C3435T polymorphism and
the pharmacokinetics of docetaxel was observed in premenopausal
women (Kruskal–Wallis test P¼0.0002 for AUC, Table 3).
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Figure 1 The aera under the plasma concentration-time curve (AUC) of docetaxel according to C3435T polymorphism and menopausal status. In (A)
exclusion of the outlier patient with an AUC 434000mghl
–1 did not alter the P-value. (A) Premenopausal patients. (B) Postmenopausal patients.
Table 2 Number of patients for each genotype of ABCB1
polymorphisms
Polymorphism Genotype Number (%)
T-129C
TT 74 (86)
TC 11 (13)
CC 1 (1)
A61G AA 78 (91)
AG 8 (9)
GG 0 (0)
C1236T CC 35 (41)
CT 38 (44)
TT 13 (15)
G2677T/A GG 43 (50)
GT 32 (37)
TT 10 (12)
TA 1 (1)
C3435T CC 34 (40)
CT 39 (45)
TT 13 (15)
61–1236–2677–3435 AA-CC-GG-CC 24 (28)
61–1236–2677–3435 AA-CT-GT-CT 19 (22)
1236–2677–3435 TT-TT-TT 7 (8)
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sThe AUC of docetaxel was lower for 3435CC patients than for
3435CT and 3435TT patients considered as a single group (Mann-
Whitney test Po0.0001, Figure 1A). In postmenopausal women, no
significant relationship was found between the pharmacokinetics
of docetaxel and C3435T polymorphism (Figure 1B, Table 4).
Analysis of the most frequent ethnic group in the study
population, that is, Caucasians, showed that the relationship
between 3435CC genotype and lower AUC remained significant in
premenopausal women (AUC ± s.e. values (mghl
–1): 2816±149
and 5094±1050 for 3435CC (n¼10) vs 3435CT and 3435TT
(n¼30), respectively, Mann–Whitney test P¼0.004).
Comparison between pre- and postmenopausal women with the
same C3435T genotype yielded a significant difference in docetaxel
AUC for CC genotype (Mann–Whitney test Po0.0001) with
lower AUC in premenopausal women (see Tables 3 and 4: mean
AUC (s.e.)¼2727mghl
–1 (104) vs 5075mghl
–1 (481) for pre- vs
Table 3 Pharmacokinetics of docetaxel according to ABCB1 polymorph-
isms for premenopausal patients
Premenopausal patients (n¼53)
AUC (lghl
–1) Clearance (lh
–1)
Genotype (n) Mean (s.e.) P* Mean (s.e.) P*
T-129C
TT (48) 4251 (673) 50.8 (2.6)
TC (4) 2779 (330) 0.4 52.8 (5.4) 0.8
CC (1) 3410 58.6
A61G
AA (47) 4119 (685) 51.6 (2.6)
AG (6) 4163(751) 0.4 47.4 (6.5) 0.6
GG (0)
C1236T
CC (21) 3148 (236) 56.1 (4.0)
CT (24) 5115 (1316) 0.09 48.2 (3.6) 0.3
TT (8) 3713 (380) 46.6 (3.2)
G2677T/A
GG (26) 3093 (192) 56.9 (3.3)
GT (20) 5560 (1566) 0.02 45.8 (4.1) 0.05
TT (7) 3849 (410) 44.7 (3.2)
TA (0)
GG (26) 3093 (192) 0.005 56.9 (3.3) 0.02
GT and TT and TA (27) 5117 (1166) 46.3 (3.1)
C3435T
CC (21) 2727 (104) 61.9 (3.0)
CT (25) 5431 (1248) 0.0002 42.9 (3.4) 0.0008
TT (7) 3647 (455) 47.8 (4.4)
CC (21) 2727 (104) o0.0001 61.9 (3.0) 0.0002
CT and TT (32) 5041 (984) 44.0 (2.8)
2677–3435
GG-CC (21) 2727 (104) o0.0001 61.9 (3.0) 0.0002
Others (32) 5041 (984) 44.0 (2.8)
61–1236–2677–3435
AA-CC-GG-CC (15) 2638 (131) 0.0002 63.3 (3.9) 0.002
Others (38) 4711 (836) 46.3 (2.6)
61–1236–2677–3435
AA-CT-GT-CT (13) 6549 (2377) 0.06 43.5 (5.7) 0.08
Others (40) 3336 (179) 53.6 (2.5)
1236–2677–3435
CT-GT-CT (17) 5995 (1829) 0.02 44.1 (4.6) 0.06
Others (36) 3241 (166) 54.4 (2.6)
1236–2677–3435
TT-TT-TT (4) 4097 (725) 0.4 42.4 (5.3) 0.2
Others (49) 4126 (660) 51.8 (2.5)
Abbreviations: AUC¼plasma concentration-time curve; s.e.¼standard error.
*Comparisons between groups used the Mann–Whitney test for two groups and
the Kruskal–Wallis test for three or more groups. Statistical significance was defined
as Po0.005 (P values in bold when Po0.005).
Table 4 Pharmacokinetics of docetaxel according to ABCB1 polymor-
phisms for postmenopausal patients
Postmenopausal patients (n¼33)
AUC (lghl
–1) Clearance (lh
–1)
Genotype (n) Mean (s.e.) P* Mean (s.e.) P*
T-129C
TT (26) 4635 (351) 0.8 41.5 (3.4) 0.5
TC (7) 4462 (565) 45.7 (5.9)
CC (0)
A61G
AA (31) 4588 (317) 0.4 43.0 (3.1) 0.4
AG (2) 4765 (15) 33.6 (0.1)
GG (0)
C1236T
CC (14) 4733 (511) 42.2 (4.4)
CT (14) 4675 (461) 0.9 41.8 (4.7) 0.9
TT (5) 4006 (517) 44.8 (8.7)
G2677T/A
GG (17) 4612 (425) 42.0 (3.6)
GT (12) 4228 (414) 0.4 46.2 (5.9) 0.4
TT (3) 4553 (476) 36.9 (5.0)
TA (1) 8943 20.1
GG (17) 4612 (425) 0.8 42.0 (3.6) 0.8
GT and TT and TA (16) 4584 (431) 42.8 (4.8)
C3435T
CC (13) 5075 (481) 36.7 (2.8)
CT (14) 4279 (492) 0.2 46.9 (4.9) 0.3
TT (6) 4309 (539) 44.3 (9.4)
CC (13) 5075 (481) 0.1 36.7 (2.8) 0.2
CT and TT (20) 4288 (373) 46.1 (4.3)
2677–3435
GG-CC (12) 5141 (517) 0.1 36.4 (3.0) 0.2
Others (21) 4288 (356) 45.8 (4.1)
61–1236–2677–3435
AA-CC-GG-CC (9) 5507 (645) 0.04 34.7 (3.9) 0.09
Others (24) 4257 (311) 45.3 (3.6)
61–1236–2677–3435
AA-CT-GT-CT (6) 4649 (593) 0.8 41.0 (5.8) 0.9
Others (27) 4587 (344) 42.7 (3.4)
1236–2677–3435
CT-GT-CT (6) 4649 (593) 0.8 41.0 (5.8) 0.9
Others (27) 4587 (344) 42.7 (3.4)
1236–2677–3435
TT-TT-TT (3) 4553 (476) 0.7 36.9 (5.0) 0.6
Others (30) 4603 (326) 43.0 (3.2)
Abbreviations: AUC¼plasma concentration-time curve; s.e.¼standard error.
*Comparisons between groups used the Mann–Whitney test for two groups and
the Kruskal–Wallis test for three or more groups. Statistical significance was defined
as Po0.005.
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spostmenopausal 3435CC women, respectively). In contrast, no
difference in docetaxel AUC was observed between pre- and
postmenopausal women with CT genotype (Mann–Whitney test
P¼0.8) and between pre- and postmenopausal women with TT
genotype (Mann–Whitney test P¼0.4) (see Tables 3 and 4: mean
AUC (s.e.)¼5431mghl
–1 (1248) and 4279mghl
–1 (492) for
pre- vs postmenopausal 3435CT women, respectively, and
3647mghl
–1 (455) and 4309mghl
–1 (539) for pre- vs postmeno-
pausal 3435TT women, respectively).
No significant association (Po0.005) was found between the
other polymorphisms analysed and docetaxel pharmacokinetics in
premenopausal women (Table 3) or in postmenopausal women
(Table 4). The 2677GG-3435CC diplotype and the most frequent
61AA-1236CC-2677GG-3435CC haplotype were significantly asso-
ciated with lower AUC of docetaxel in premenopausal women
(Table 3).
Analysis of the overall population did not show any significant
relationship (Po0.005) between the pharmacokinetics of docetaxel
and any of the ABCB1 polymorphisms or any combination of
ABCB1 genotypes (Table 5).
DISCUSSION
This study shows an effect of menopausal status at diagnosis on
the relationship between C3435T polymorphism of ABCB1 gene
and the pharmacokinetics of docetaxel in breast cancer patients.
When evaluating the overall population, no association was
observed between C3435T polymorphism and the pharmaco-
kinetics of docetaxel, which is in accordance with the few
published studies on this topic (Goh et al, 2002; Bosch et al,
2006; Tran et al, 2006; Lewis et al, 2007). In contrast, when
analysing the population according to menopausal status at time of
diagnosis of breast cancer, a highly significant association with
docetaxel pharmacokinetics was observed in premenopausal
women for this polymorphism (Po0.0001), but not in postmeno-
pausal women. Comparison of pre- and postmenopausal women
with the same C3435T genotype yielded a significant difference in
docetaxel AUC only for the CC genotype (Po0.0001) and not for
the CT or TT genotypes. Premenopausal CC women had
significantly lower AUC than premenopausal (CT and TT) women
and CC postmenopausal women. Premenopausal (CT and TT)
women had similar AUC to those of postmenopausal CC and
postmenopausal (CT and TT) women (see Figure 1). To the best of
our knowledge, this is the first report of a specific effect of
menopausal status at the time of diagnosis on the role of ABCB1
polymorphisms in docetaxel disposition. By contrast, such an
effect was not observed for doxorubicin in these patients (data not
shown), which suggests that the effect is drug specific. A significant
relationship (P¼0.001) between docetaxel pharmacokinetics and
C3435T genotype was also found for patients younger than 49
years, which was the mean age at diagnosis (data not shown). As
this age is also the mean value of age at menopause, we believe that
menopausal status at diagnosis rather than age has an effect on
docetaxel pharmacokinetics.
The finding of a highly significant association in premenopausal
women between lower AUC of docetaxel and 2677GG-3435CC
diplotype and 61AA-1236CC-2677GG-3435CC haplotype is
probably because of the strong linkage between these genotypes
(Kroetz et al, 2003), although this remains to be evaluated
in a large series of women receiving docetaxel neoadjuvant
chemotherapy.
The 3435CC genotype has usually been associated with higher
levels of ABCB1 mRNA and protein and increased drug efflux in
normal tissues and tumours (Hoffmeyer et al, 2000; Hitzl et al,
2001; Tanabe et al, 2001; Fellay et al, 2002; Vaclavikova et al, 2008),
although some discrepancies have been reported, especially in
Japanese populations (Nakamura et al, 2002). It therefore makes
sense to observe lower AUC of docetaxel in CC patients, as their
higher levels of ABCB1 in organs involved in drug metabolism
would result in higher efflux of docetaxel, higher elimination of the
drug and subsequently lower AUC. The mechanisms by which this
synonymous polymorphism affects ABCB1 function might be a
lower mRNA stability of the 3435T variant (Wang et al, 2005)
and/or a change in substrate binding site conformation of the
variant ABCB1 protein (Kimchi-Sarfaty et al, 2007). This different
protein folding could be due to a different rate of translation when
Table 5 Pharmacokinetics of docetaxel according to ABCB1
polymorphisms for the overall population
Overall population (n¼86)
AUC (lghl
–1) Clearance (lh
–1)
Genotype (n) Mean (s.e.) P* Mean (s.e.) P*
T-129C
TT (74) 4386 (452) 47.5 (2.1)
TC (11) 3850 (447) 0.9 48.3 (4.2) 0.6
CC (1) 3410 58.6
A61G
AA (78) 4305 (431) 48.1 (2.0)
AG (8) 4314 (558) 0.4 44.0 (5.3) 0.5
GG (0)
C1236T
CC (35) 3782 (278) 50.5 (3.2)
CT (38) 4953 (842) 0.4 45.8 (2.9) 0.5
TT (13) 3825 (297) 45.9 (3.7)
G2677T/A
GG (43) 3693 (232) 51.0 (2.7)
GT (32) 5061 (988) 0.1 45.9 (3.3) 0.2
TT (10) 4060 (324) 42.3 (2.8)
TA (1) 8943 20.1
GG (43) 3693 (232) 0.06 51.0 (2.7) 0.08
GT and TT and TA (43) 4919 (745) 44.5 (2.6)
C3435T
CC (34) 3625 (275) 52.2 (3.0)
CT (39) 5018 (817) 0.09 44.4 (2.8) 0.2
TT (13) 3953 (347) 46.2 (4.7)
CC (34) 3625 (275) 0.03 52.2 (3.0) 0.06
CT and TT (52) 4752 (620) 44.8 (2.4)
2677–3435
GG-CC (33) 3605 (283) 0.02 52.6 (3.1) 0.04
Others (53) 4743 (608) 44.7 (2.3)
61–1236–2677–3435
AA-CC-GG-CC (24) 3714 (380) 0.09 52.6 (4.0) 0.2
Others (62) 4535 (524) 45.9 (2.1)
61–1236–2677–3435
AA-CT-GT-CT (19) 5949 (1628) 0.1 42.7 (4.2) 0.2
Others (67) 3840 (189) 49.2 (2.1)
1236–2677–3435
CT-GT-CT (23) 5644 (1355) 0.1 43.3 (3.7) 0.2
Others (63) 3818 (193) 49.4 (2.2)
1236–2677–3435
TT-TT-TT (7) 4293 (437) 0.3 40.0 (3.6) 0.2
Others (79) 4307 (427) 48.4 (2.0)
Abbreviations: AUC¼plasma concentration-time curve; s.e.¼standard error.
*Comparisons between groups used the Mann–Whitney test for two groups and
the Kruskal–Wallis test for three or more groups. Statistical significance was defined
as Po0.005.
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srare codons are used which might be at least partly because of
ribosome stalling (Fung and Gottesman, 2009).
Why lower AUC of docetaxel were specifically observed
in premenopausal CC women and not in postmenopausal
CC women is still unknown. A role for oestrogen and progesterone
in modulating ABCB1 expression and function has been shown in
various cells with increased ABCB1 expression induced by
oestrogen and progesterone at both the mRNA and protein
levels (Arceci et al, 1990; Kim and Benet, 2004; Evseenko et al,
2007). It may be hypothesised that this inductive action of
oestrogen and progesterone on ABCB1 could at least partly
explain the lower AUC of docetaxel observed in premenopausal
women compared with postmenopausal women independently of
any effect of C3435T polymorphism. Higher oestrogen and
progesterone levels in premenopausal women would induce
higher ABCB1 levels and consequently higher efflux of docetaxel.
It can be hypothesised that the finding of lower docetaxel AUC
only in premenopausal CC women might be due to an additive
effect of genotype and hormones on ABCB1 overexpression.
However, the hypothesised role of oestrogen and progesterone on
docetaxel pharmacokinetics through ABCB1 expression must
be interpreted in the light that these women had received previous
chemotherapy inducing a possible decrease in oestrogen
and progesterone production in premenopausal women (Fornier
et al, 2005).
A significant association between C1236T polymorphism and
docetaxel clearance was reported by Bosch et al (2006), as patients
homozygous for the variant T allele showed lower clearance. In the
present series, in accordance with this report, patients homo-
zygous for the T allele presented a lower docetaxel clearance
although not reaching statistical significance (see Table 5).
In conclusion, these results show that menopausal status
at diagnosis has an impact on the effect of C3435T polymorphism
of ABCB1 gene on the pharmacokinetics of docetaxel in breast
cancer patients. This finding raises the question of whether higher
doses of docetaxel should be given to 3435CC premenopausal
women. To provide further insight into this issue, we are currently
analysing whether C3435T polymorphism is involved in the
pathologic response of breast cancer patients receiving docetaxel
in their neoadjuvant chemotherapy regimen according to their
menopausal status.
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